Model Medicines Highlighted as VC Backed StartUp Battling COVID-19 by MedCityNews

How are healthcare VCs in every sector handling COVID-19?

A number of venture capital firms said they’re still open for business, in spite of the Covid-19 pandemic. But deal-making has slowed substantially, as companies weigh what will be needed to survive the coming months. How you invest in the midst of a health crisis that has left a third of the U.S. population stuck at home, and with many businesses struggling?

MedCity News interviewed venture capital firms focused on digital health, biotechnology and medtech by phone and by email. Six investors shared their strategies for weathering this storm, and what advice they’re giving portfolio companies.


This article originally appeared on MedCity News, prior to the rebrand of Repurpose.AI to Model Medicines, read the full article here.

Previous
Previous

Model Medicines COVID-19 Drug Development Program Highlighted by Catalyst Health 2.0

Next
Next

Model Medicines COVID-19 Drug Development Program Highlighted by FreshBrewedTech